Diabetic Macular Edema Market Indication Type, Treatment Type, and End User - Global Industry Analysis and Forecast to 2027
Published On : September 2017 Pages : 105 Category: Medical Devices Report Code : HC0682
Industry Trend Analysis
The global diabetic macular edema (DME) market is expected to be around $4 billion by 2027. Some of the key factors driving this market are high prevalence of diabetic retinopathy and diabetic macular edema and increasing prevalence of geriatric population around the world. According to the National Center for biotechnology Information, DME is expected to affect around 592 million people by 2035. With such high incidence of DME, the demand for therapies to treat DME is expected to considerably increase during the forecast period. Older adults are more susceptible to diabetes. With increasing prevalence of older population globally, the risk of DME is also expected to increase during the forecast period.
Indication Type Outlook and Trend Analysis
Based on the indication type, the global diabetic macular edema market is segmented into diffuse diabetic macular edema and focal diabetic macular edema. Focal macular edema is caused due to leakage from microaneurysms which results in hard exudate rings. It is caused due to foci of vascular abnormalities which are associated with an abnormally high permeability. Diffused macular edema is caused due to dilated retinal capillaries. It is a result of leakage from arterioles, capillaries and microaneurysms.
Treatment Type Outlook and Trend Analysis
Corticosteroid therapy can be used to treat patients suffering from recurrent or advanced DME. Corticosteroids are anti-inflammatory non-specific agents and can be effective when administered intravitreally. Grid laser photocoagulation is a standard therapy used for treatment of DME. The laser is applied in a grid-like pattern in order to clear scars that lead to vision loss and blind spots and to destroy the damaged tissue. Implants filled with drugs are also widely used for treating patients with DME caused due to retinal vein occlusion which is one of the common causes leading to macular edema.
Regional Outlook and Trend Analysis
North America held a substantial share of the global DME market in 2017 owing to high prevalence of diabetes, high awareness among people about DME and the available treatment options and better reimbursement policies in the region. The region is expected to maintain its dominance over the market during the forecast period. European DME market is expected to show lucrative growth during the forecast period owing to presence of large patient pool in the region.
Competitive Analysis
The key strategy followed by the players operating in the global DME market is product development. These players develop advanced products and therapies to effectively treat recurring or advanced DME and in turn, occupy a larger share of the market. For instance, in February 2017, Genentech, Inc., a subsidiary of the Roche group obtained FDA approval for their Lucentis (ranibizumab injection) 0.3 mg for treating diabetic retinopathy in patients affected by DME. It is administered as an injection by a physician once a month. Some of the key players operating in this market are, Bayer AG, F. Hoffmann-La Roche Ltd., Alimera Sciences, Inc., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Allergan plc, Novartis AG and Bausch & Lomb Incorporated (acquired by Valeant Pharmaceuticals International, Inc.).
Diabetic Macular Edema Market Segmentation:
By Indication Type:
- Diffuse Diabetic Macular Edema
- Focal Diabetic Macular Edema
By Treatment Type:
- Corticosteroid Therapy
- Grid Laser Photocoagulation
- Implants
- Anti-vascular Endothelial Growth Factor Therapy
- Focal Laser Treatment
By End User:
- Ophthalmic Clinics
- Hospitals
- Ambulatory Surgical Centers
By Region:
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- United Arab Emirates
- Others
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2022 to 2027?
- What will be the industry market growth from 2022 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
- Diabetic Macular Edema Market By Indication Type, Estimates and Forecast, 2017-2027 ($Million)
- Diffuse Diabetic Macular Edema
- Focal Diabetic Macular Edema
- Diabetic Macular Edema Market By Treatment Type, Estimates and Forecast, 2017-2027 ($Million)
- Corticosteroid Therapy
- Grid Laser Photocoagulation
- Implants
- Anti-vascular Endothelial Growth Factor Therapy
- Focal Laser Treatment
- Diabetic Macular Edema Market By End User, Estimates and Forecast, 2017-2027 ($Million)
- Ophthalmic Clinics
- Hospitals
- Ambulatory Surgical Centers
- Diabetic Macular Edema Market By Region, Estimates and Forecast, 2017-2027 ($Million)
- North America
- North America Diabetic Macular Edema Market, By Country
- North America Diabetic Macular Edema Market, By Indication Type
- North America Diabetic Macular Edema Market, By Treatment Type
- North America Diabetic Macular Edema Market, By End User
- U.S. Diabetic Macular Edema Market, By Indication Type
- U.S. Diabetic Macular Edema Market, By Treatment Type
- U.S. Diabetic Macular Edema Market, By End User
- Canada Diabetic Macular Edema Market, By Indication Type
- Canada Diabetic Macular Edema Market, By Treatment Type
- Canada Diabetic Macular Edema Market, By End User
- Mexico Diabetic Macular Edema Market, By Indication Type
- Mexico Diabetic Macular Edema Market, By Treatment Type
- Mexico Diabetic Macular Edema Market, By End User
-
- Europe
- Europe Diabetic Macular Edema Market, By Country
- Europe Diabetic Macular Edema Market, By Indication Type
- Europe Diabetic Macular Edema Market, By Treatment Type
- Europe Diabetic Macular Edema Market, By End User
- Germany Diabetic Macular Edema Market, By Indication Type
- Germany Diabetic Macular Edema Market, By Treatment Type
- Germany Diabetic Macular Edema Market, By End User
- France Diabetic Macular Edema Market, By Indication Type
- France Diabetic Macular Edema Market, By Treatment Type
- France Diabetic Macular Edema Market, By End User
- UK Diabetic Macular Edema Market, By Indication Type
- UK Diabetic Macular Edema Market, By Treatment Type
- UK Diabetic Macular Edema Market, By End User
- Italy Diabetic Macular Edema Market, By Indication Type
- Italy Diabetic Macular Edema Market, By Treatment Type
- Italy Diabetic Macular Edema Market, By End User
- Spain Diabetic Macular Edema Market, By Indication Type
- Spain Diabetic Macular Edema Market, By Treatment Type
- Spain Diabetic Macular Edema Market, By End User
- Rest of Europe Diabetic Macular Edema Market, By Indication Type
- Rest of Europe Diabetic Macular Edema Market, By Treatment Type
- Rest of Europe Diabetic Macular Edema Market, By End User
-
- Asia-Pacific
- Asia-Pacific Diabetic Macular Edema Market, By Country
- Asia-Pacific Diabetic Macular Edema Market, By Indication Type
- Asia-Pacific Diabetic Macular Edema Market, By Treatment Type
- Asia-Pacific Diabetic Macular Edema Market, By End User
- Japan Diabetic Macular Edema Market, By Indication Type
- Japan Diabetic Macular Edema Market, By Treatment Type
- Japan Diabetic Macular Edema Market, By End User
- China Diabetic Macular Edema Market, By Indication Type
- China Diabetic Macular Edema Market, By Treatment Type
- China Diabetic Macular Edema Market, By End User
- Australia Diabetic Macular Edema Market, By Indication Type
- Australia Diabetic Macular Edema Market, By Treatment Type
- Australia Diabetic Macular Edema Market, By End User
- India Diabetic Macular Edema Market, By Indication Type
- India Diabetic Macular Edema Market, By Treatment Type
- India Diabetic Macular Edema Market, By End User
- South Korea Diabetic Macular Edema Market, By Indication Type
- South Korea Diabetic Macular Edema Market, By Treatment Type
- South Korea Diabetic Macular Edema Market, By End User
- Rest of Asia-Pacific Diabetic Macular Edema Market, By Indication Type
- Rest of Asia-Pacific Diabetic Macular Edema Market, By Treatment Type
- Rest of Asia-Pacific Diabetic Macular Edema Market, By End User
- Asia-Pacific
-
- Rest of the World
- Rest of the World Diabetic Macular Edema Market, By Country
- Rest of the World Diabetic Macular Edema Market, By Indication Type
- Rest of the World Diabetic Macular Edema Market, By Treatment Type
- Rest of the World Diabetic Macular Edema Market, By End User
- Brazil Diabetic Macular Edema Market, By Indication Type
- Brazil Diabetic Macular Edema Market, By Treatment Type
- Brazil Diabetic Macular Edema Market, By End User
- South Africa Diabetic Macular Edema Market, By Indication Type
- South Africa Diabetic Macular Edema Market, By Treatment Type
- South Africa Diabetic Macular Edema Market, By End User
- Saudi Arabia Diabetic Macular Edema Market, By Indication Type
- Saudi Arabia Diabetic Macular Edema Market, By Treatment Type
- Saudi Arabia Diabetic Macular Edema Market, By End User
- Turkey Diabetic Macular Edema Market, By Indication Type
- Turkey Diabetic Macular Edema Market, By Treatment Type
- Turkey Diabetic Macular Edema Market, By End User
- United Arab Emirates Diabetic Macular Edema Market, By Indication Type
- United Arab Emirates Diabetic Macular Edema Market, By Treatment Type
- United Arab Emirates Diabetic Macular Edema Market, By End User
- Others Diabetic Macular Edema Market, By Indication Type
- Others Diabetic Macular Edema Market, By Treatment Type
- Others Diabetic Macular Edema Market, By End User
- Rest of the World
Table of Contents
1.Introduction
1.1.Report Description
1.2.Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2.Executive Summary
2.1.Key Highlights
3.Market Overview
3.1.Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2.Market Share Analysis
3.3.Market Dynamics
3.3.1. Drivers
3.3.1.1.High Prevalence of Diabetic Retinopathy and Diabetic Macular Edema
3.3.1.2.Rise in Aging Population Globally
3.3.2. Restraints
3.3.2.1.Unfavorable Reimbursement Policies
3.3.3. Opportunities
3.3.3.1.Rising Awareness about Diabetic Macular Edema and Available Products and Therapies
3.4.Industry Trends
4.Diabetic Macular Edema Market, By Indication Type
4.1.Introduction
4.2.Diabetic Macular Edema Market Assessment and Forecast, By Indication Type, 2017-2027
4.3.Diffuse Diabetic Macular Edema
4.3.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
4.4.Focal Diabetic Macular Edema
4.4.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.Diabetic Macular Edema Market, By Treatment Type
5.1.Introduction
5.2.Diabetic Macular Edema Market Assessment and Forecast, By Treatment Type, 2017-2027
5.3.Corticosteroid Therapy
5.3.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.4.Grid Laser Photocoagulation
5.4.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.5.Implants
5.5.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.6.Anti-vascular Endothelial Growth Factor Therapy
5.6.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.7.Focal Laser Treatment
5.7.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
6.Diabetic Macular Edema Market, By End User
6.1.Introduction
6.2.Diabetic Macular Edema Market Assessment and Forecast, By End User, 2017-2027
6.3.Ophthalmic Clinics
6.3.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
6.4.Hospitals
6.4.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
6.5.Ambulatory Surgical Centers
6.5.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
7.Diabetic Macular Edema Market, By Region
7.1.Introduction
7.2.Diabetic Macular Edema Market Assessment and Forecast, By Region, 2017-2027 ($Million)
7.3.North America
7.3.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
7.3.2. Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.3.3. Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.3.4. Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.3.4.1.U.S.
7.3.4.1.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.3.4.1.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.3.4.1.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.3.4.2.Canada
7.3.4.2.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.3.4.2.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.3.4.2.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.3.4.3.Mexico
7.3.4.3.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.3.4.3.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.3.4.3.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.Europe
7.4.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
7.4.2. Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.3. Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4. Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.4.1.Germany
7.4.4.1.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.4.1.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4.1.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.4.2.France
7.4.4.2.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.4.2.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4.2.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.4.3.UK
7.4.4.3.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.4.3.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4.3.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.4.4.Italy
7.4.4.4.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.4.4.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4.4.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.4.5.Spain
7.4.4.5.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.4.5.2.Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4.5.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.4.6.Russia
7.4.4.6.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.4.6.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4.6.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.4.4.7.Rest of Europe
7.4.4.7.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.4.4.7.2.Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.4.4.7.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.Asia-Pacific
7.5.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
7.5.2. Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.3. Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4. Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.4.1.Japan
7.5.4.1.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.4.1.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4.1.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.4.2.China
7.5.4.2.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.4.2.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4.2.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.4.3.Australia
7.5.4.3.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.4.3.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4.3.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.4.4.India
7.5.4.4.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.4.4.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4.4.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.4.5.South Korea
7.5.4.5.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.4.5.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4.5.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.4.6.Taiwan
7.5.4.6.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.4.6.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4.6.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.5.4.7.Rest of Asia-Pacific
7.5.4.7.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.5.4.7.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.5.4.7.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.6.Rest of the World
7.6.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
7.6.2. Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.6.3. Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.6.4. Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.6.4.1.Brazil
7.6.4.1.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.6.4.1.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.6.4.1.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.6.4.2.Turkey
7.6.4.2.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.6.4.2.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.6.4.2.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.6.4.3.Saudi Arabia
7.6.4.3.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.6.4.3.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.6.4.3.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.6.4.4.South Africa
7.6.4.4.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.6.4.4.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.6.4.4.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.6.4.5.United Arab Emirates
7.6.4.5.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.6.4.5.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.6.4.5.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
7.6.4.6.Others
7.6.4.6.1.Market Assessment and Forecast, By Indication Type, 2017-2027 ($Million)
7.6.4.6.2.Market Assessment and Forecast, By Treatment Type, 2017-2027 ($Million)
7.6.4.6.3.Market Assessment and Forecast, By End User, 2017-2027 ($Million)
8.Company Profiles
8.1.Bayer AG
8.1.1. Business Overview
8.1.2. Product Portfolio
8.1.3. Key Financials
8.1.4. Strategic Developments
8.2.F. Hoffmann-La Roche Ltd.
8.2.1. Business Overview
8.2.2. Product Portfolio
8.2.3. Key Financials
8.2.4. Strategic Developments
8.3.Alimera Sciences, Inc.
8.3.1. Business Overview
8.3.2. Product Portfolio
8.3.3. Strategic Developments
8.4.Regeneron Pharmaceuticals, Inc.
8.4.1. Business Overview
8.4.2. Product Portfolio
8.4.3. Key Financials
8.4.4. Strategic Developments
8.5.Pfizer Inc.
8.5.1. Business Overview
8.5.2. Product Portfolio
8.5.3. Key Financials
8.5.4. Strategic Developments
8.6.Allergan plc
8.6.1. Business Overview
8.6.2. Product Portfolio
8.6.3. Key Financials
8.6.4. Strategic Developments
8.7.Novartis AG
8.7.1. Business Overview
8.7.2. Product Portfolio
8.7.3. Key Financials
8.7.4. Strategic Developments
8.8.Bausch & Lomb Incorporated
8.8.1. Business Overview
8.8.2. Product Portfolio
8.8.3. Key Financials
8.8.4. Strategic Developments
List of Tables
Table 1.Global Diabetic Macular Edema Market, By Indication Type ($Million), 2017-2025
Table 2.Diffuse Diabetic Macular Edema Market, By Region ($Million), 2017-2025
Table 3.Focal Diabetic Macular Edema Market, By Region ($Million), 2017-2025
Table 4.Global Diabetic Macular Edema Market, By Treatment Type ($Million), 2017-2025
Table 5.Corticosteroid Therapy Market, By Region ($Million), 2017-2025
Table 6.Grid Laser Photocoagulation Market, By Region ($Million), 2017-2025
Table 7.Implants Market, By Region ($Million), 2017-2025
Table 8.Anti-vascular Endothelial Growth Factor Therapy Market, By Region ($Million), 2017-2025
Table 9.Focal Laser Treatment Market, By Region ($Million), 2017-2025
Table 10.Global Diabetic Macular Edema Market, By End User ($Million), 2017-2025
Table 11.Ophthalmic Clinics Market, By Region ($Million), 2017-2025
Table 12.Hospitals Market, By Region ($Million), 2017-2025
Table 13.Ambulatory Surgical Centers Market, By Region ($Million), 2017-2025
Table 14.Diabetic Macular Edema Market, By Region, 2017-2025 ($Million)
Table 15.North America Diabetic Macular Edema Market, By Country, 2017-2025 ($Million)
Table 16.North America Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 17.North America Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 18.North America Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 19.U.S. Diabetes devices market, by Indication Type, 2017-2025 ($Million)
Table 20.U.S. Diabetes devices market, by Treatment Type, 2017-2025 ($Million)
Table 21.U.S. Diabetes devices market, by End User, 2017-2025 ($Million)
Table 22.Canada Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 23.Canada Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 24.Canada Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 25.Mexico Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 26.Mexico Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 27.Mexico Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 28.Europe Diabetic Macular Edema Market, By Country, 2017-2025 ($Million)
Table 29.Europe Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 30.Europe Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 31.Europe Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 32.Germany Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 33.Germany Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 34.Germany Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 35.France Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 36.France Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 37.France Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 38.UK Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 39.UK Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 40.UK Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 41.Italy Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 42.Italy Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 43.Italy Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 44.Spain Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 45.Spain Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 46.Spain Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 47.Russia Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 48.Russia Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 49.Russia Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 50.Rest of Europe Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 51.Rest of Europe Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 52.Rest of Europe Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 53.Asia-Pacific Diabetic Macular Edema Market, By Country, 2017-2025 ($Million)
Table 54.Asia-Pacific Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 55.Asia-Pacific Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 56.Asia-Pacific Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 57.Japan Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 58.Japan Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 59.Japan Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 60.China Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 61.China Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 62.China Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 63.Australia Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 64.Australia Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 65.Australia Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 66.India Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 67.India Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 68.India Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 69.South Korea Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 70.South Korea Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 71.South Korea Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 72.Taiwan Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 73.Taiwan Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 74.Taiwan Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 75.Rest of Asia-Pacific Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 76.Rest of Asia-Pacific Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 77.Rest of Asia-Pacific Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 78.Rest of the World Diabetic Macular Edema Market, By Country, 2017-2025 ($Million)
Table 79.Rest of the World Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 80.Rest of the World Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 81.Rest of the World Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 82.Brazil Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 83.Brazil Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 84.Brazil Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 85.Turkey Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 86.Turkey Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 87.Turkey Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 88.Saudi Arabia Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 89.Saudi Arabia Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 90.Saudi Arabia Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 91.South Africa Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 92.South Africa Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 93.South Africa Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 94.United Arab Emirates Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 95.United Arab Emirates Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 97.United Arab Emirates Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 98.Others Diabetic Macular Edema Market, By Indication Type, 2017-2025 ($Million)
Table 99.Others Diabetic Macular Edema Market, By Treatment Type, 2017-2025 ($Million)
Table 100.Others Diabetic Macular Edema Market, By End User, 2017-2025 ($Million)
Table 101.Bayer AG: Key Strategic Developments, 2017-2017
Table 102.F. Hoffmann-La Roche Ltd.: Key Strategic Developments, 2017-2017
Table 103.Alimera Sciences, Inc.: Key Strategic Developments, 2017-2017
Table 104.Regeneron Pharmaceuticals, Inc.: Key Strategic Developments, 2017-2017
Table 105.Pfizer Inc.: Key Strategic Developments, 2017-2017
Table 106.Allergan plc: Key Strategic Developments, 2017-2017
Table 107.Novartis AG: Key Strategic Developments, 2017-2017
Table 108.Bausch & Lomb Incorporated: Key Strategic Developments, 2017-2017
List of Figures
Figure 1.Global Diabetic Macular Edema Market Share, By Indication Type, 2017 & 2025
Figure 2.Diabetic Macular Edema Market, By Treatment Type, 2017, ($Million)
Figure 3.Diabetic Macular Edema Market, By End User, 2017, ($Million)
Figure 4.Diabetic Macular Edema Market, By Region, 2017, ($Million)
Figure 5.Bayer AG: Net Revenues, 2017-2017 ($Million)
Figure 6.Bayer AG: Net Revenue Share, By Segment, 2017
Figure 7.Bayer AG: Net Revenue Share, By Geography, 2017
Figure 8.F. Hoffmann-La Roche Ltd.: Net Revenues, 2017-2017 ($Million)
Figure 9.F. Hoffmann-La Roche Ltd.: Net Revenue Share, By Segment, 2017
Figure 10.F. Hoffmann-La Roche Ltd.: Net Revenue Share, By Geography, 2017
Figure 11.Regeneron Pharmaceuticals, Inc.: Net Revenues, 2017-2017 ($Million)
Figure 12.Regeneron Pharmaceuticals, Inc.: Net Revenue Share, By Segment, 2017
Figure 13.Regeneron Pharmaceuticals, Inc.: Net Revenue Share, By Geography, 2017
Figure 14.Pfizer Inc.: Net Revenues, 2017-2017 ($Million)
Figure 15.Pfizer Inc.: Net Revenue Share, By Segment, 2017
Figure 16.Pfizer Inc.: Net Revenue Share, By Geography, 2017
Figure 17.Allergan plc: Net Revenues, 2017-2017 ($Million)
Figure 18.Allergan plc: Net Revenue Share, By Segment, 2017
Figure 19.Allergan plc: Net Revenue Share, By Geography, 2017
Figure 20.Novartis AG: Net Revenues, 2017-2017 ($Million)
Figure 21.Novartis AG: Net Revenue Share, By Segment, 2017
Figure 22.Novartis AG: Net Revenue Share, By Geography, 2017
Figure 23.Bausch & Lomb Incorporated: Net Revenues, 2017-2017 ($Million)
Figure 24.Bausch & Lomb Incorporated: Net Revenue Share, By Segment, 2017
Figure 25.Bausch & Lomb Incorporated: Net Revenue Share, By Geography, 2017
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|